|
|
Article: DNA vaccine trial initiated for treatment of herpes simplex type 2.
- Article from:
- Drug Week
- Article date:
- November 12, 2004
CopyrightCOPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2004 NOV 12 - (NewsRx.com & NewsRx.net) -- PowderMed Ltd (PowderMed) announced that it has initiated a phase I trial in patients of a novel therapeutic DNA vaccine for the treatment of herpes simplex type 2 (HSV2).
This therapeutic vaccine uses PowderMed's proprietary particle mediated epidermal delivery (PMED) technology to deliver a DNA plasmid coding for four HSV2 antigens.
The HSV2 trial, being carried out at The Centre for Clinical Studies in Houston, Texas is being conducted in 36 otherwise healthy individuals with recurrent genital herpes caused by HSV2. In addition to assessing the safety and tolerability of the vaccine, this study will also ...